Trial · NCT03104374
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Placebo | 24.1 | 95% Confidence Interval 18.3 to 29.8 | percentage of participants | |
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Upadacitinib 15 mg | 56.9 | 95% Confidence Interval 50.2 to 63.6 | percentage of participants | |
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Upadacitinib 30 mg | 63.8 | 95% Confidence Interval 57.4 to 70.1 | percentage of participants | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Placebo | -0.10 | 95% Confidence Interval -0.16 to -0.03 | score on a scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Upadacitinib 15 mg | -0.30 | 95% Confidence Interval -0.37 to -0.24 | score on a scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Upadacitinib 30 mg | -0.41 | 95% Confidence Interval -0.47 to -0.35 | score on a scale | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Placebo | 9.2 | 95% Confidence Interval 4.8 to 13.6 | percentage of participants | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Upadacitinib 15 mg | 36.8 | 95% Confidence Interval 29.6 to 44.1 | percentage of participants | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Upadacitinib 30 mg | 40.2 | 95% Confidence Interval 32.7 to 47.7 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Placebo | 16.0 | 95% Confidence Interval 9.7 to 22.3 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Upadacitinib 15 mg | 52.3 | 95% Confidence Interval 43.7 to 60.9 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Upadacitinib 30 mg | 56.5 | 95% Confidence Interval 48.0 to 65.0 | percentage of participants | |
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | Placebo | 1.62 | 95% Confidence Interval 0.58 to 2.67 | score on a scale | |
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | Upadacitinib 15 mg | 5.15 | 95% Confidence Interval 4.14 to 6.15 | score on a scale | |
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | Upadacitinib 30 mg | 7.06 | 95% Confidence Interval 6.07 to 8.06 | score on a scale | |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12 | Placebo | 1.3 | 95% Confidence Interval 0.1 to 2.5 | score on a scale | |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12 | Upadacitinib 15 mg | 5.0 | 95% Confidence Interval 3.8 to 6.1 | score on a scale | |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12 | Upadacitinib 30 mg | 6.1 | 95% Confidence Interval 4.9 to 7.2 | score on a scale | |
| Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24 | Placebo | 2.8 | 95% Confidence Interval 0.6 to 5.1 | percentage of participants | |
| Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24 | Upadacitinib 15 mg | 25.1 | 95% Confidence Interval 19.3 to 31.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03104374/results